**4. From the clinical setting to the market: benefits of** *H. alvei* **HA4597® for overweight to obese consumers**

As previously described, *H. alvei* HA4597® through its production of ClpB, a mimetic of the anorexigenic hormone alpha-MSH, constitutes an innovative and effective solution for body weight management in overweight and obesity. The French biotech TargEDys, pioneer in microbiome-based solutions and grounded in 15 years of academic research in collaboration with the prestigious laboratories of Inserm (Institut national de la santé et de la recherche médicale) in Rouen, developed a food supplement with 100 billion cells of *H. alvei* HA4597® per daily dose. It is the first PreciBiomic Strain product on the market for body weight management combining efficacy with no side effects. During product development, TargEDys ensured that the strain produces ClpB during the fermentation process so that both the strain and its protein ClpB are present in the product.

A consumer study confirmed the efficacy of the product in overweight people, and even in people suffering from obesity, in real life conditions, i.e., without caloric restriction. Above all, this study confirmed that the extension of the program over time intensifies the body weight loss.

### **5. Conclusion**

As concluded by the authors of the clinical trial, supplementation with the precision probiotic [20] *H. alvei* HA4597® represents an innovative and well-tolerated strategy to enhance the efficacy of dietary advice for the control of excess body weight; paving the way to precision nutrition thanks to a gut microbial-based personalized approach.
